FK614 是一种具有口服活性，有效的，选择性的 PPARγ 调制剂 (SPPARM)。FK614 对脂肪细胞分化各阶段 PPARγ 的激活有不同的影响。FK614 是一种非噻唑烷二酮类胰岛素增敏剂。FK614 可用于高血糖、高甘油三酯、葡萄糖耐受不良和 2 型糖尿病的研究。
货号:ajcx34774
CAS:193012-35-0
分子式:C21H23Cl2N3O3S
分子量：468.4
溶解度:DMSO : 100 mg/mL (213.49 mM; Need ultrasonic)
纯度：98%
存储：Store at -20°C
库存：现货

Background:

FK614 is an orally active, potent, selective PPARγ modulator (SPPARM). FK614 has different effects on the activation of PPARγ at each stage of adipocyte differentiation. FK614 is a nonthiazolidinedione insulin sensitizer. FK614 can be used for the research of hyperglycemia, hypertriglyceridemia, glucose intolerance and type 2 diabetes[1][2][3].

FK614 (0.1~10000 nM; 24 hours; CV-1 cells) activates PPARγ-dependent transcription in a concentration-dependent manner. FK614 (0~0.1 μM; 5 days; 3T3-L1 adipocytes) makes triglyceride content increased in a concentration-dependent manner. FK614 has different effects on the activation of PPARγ at each stage of adipocyte differentiation. FK614 is an insulin sensitizer potentially for treatment of postherpetic neuralgia[1][2].

FK614 (0.32~3.2 mg/kg; p.o.; 14 days) dose-dependently reduces plasma glucose level[3].FK614 (0.1~10 mg/kg; p.o.; 14 days) improves the impaired glucose tolerance[3].

[1]. Fujimura T, et al. A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties. J Pharmacol Exp Ther. 2006;318(2):863-871.
[2]. Fujimura T, et al. FK614, a novel peroxisome proliferator-activated receptor gamma modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators. J Pharmacol Sci. 2005;99(4):342-352.